Skip to content

Investor relations

Investor relations

Investor relations

Untitled design 2024 01 15T161334.059

Investor Summary

SOMAÍ Pharmaceuticals, established in 2019, has swiftly emerged as a significant player in the medical cannabis industry, focusing on the development and distribution of cannabinoid-based drug formulations. The company’s journey began with a vision to revolutionize healthcare through innovative cannabis-based treatments. Emphasizing research and clinical trials, SOMAÍ has dedicated itself to advancing the medical applications of cannabinoids.

The financial trajectory of SOMAÍ Pharmaceuticals reflects a strong commitment to growth and innovation. The company had raised 22,3 mln EUR from several private investors and private equity firms. Also SOMAÍ successfully qualified for the grant of 2,1 mln EUR from the Portugal authority.

For more detailed information and investment opportunities, please read our equity research and reach out to us via
Equity Research

Company News

Newsletter 1920 x 950 px 4

SOMAÍ Pharmaceuticals and Canify Announce Their Partnership to Introduce a Cannabinoid-Based Product Line in Germany

December 21, 2023

SOMAÍ Pharmaceuticals announces a landmark three-year marketing & distribution agreement with Canify AG. This partnership signifies SOMAÍ Pharmaceuticals’…

Read more
Newsletter 84

SOMAÍ Pharmaceuticals Enters German Market with Strategic Partnerships Securing €10 Million 2-year Distribution Deal

December 14, 2023

SOMAÍ Pharmaceuticals announces its entry into the German market through partnerships with Canymed GmbH and Grünhorn, securing a…

Read More
Newsletter 1200 x 628 px 1200 x 628 px 1920 x 950 px 1

SOMAÍ Pharmaceuticals Partners with UK’s largest medical cannabis study T21 by Drug Science

December 12, 2023

SOMAÍ Pharmaceuticals is thrilled to announce partnering with the groundbreaking medical cannabis study, T21 (formerly Project TWENTY21). As…

read more
Newsletter 82

SOMAÍ Pharmaceuticals Signs Manufacturing Contract with Canna Forest

November 28, 2023

SOMAÍ Pharmaceuticals has signed a manufacturing agreement with Canna Forest to produce EU-GMP-certified extracted cannabis APIs and products…

read more
Newsletter 48

SOMAÍ Pharmaceuticals Receives EU-GMP Certification

September 1, 2023

SOMAÍ Pharmaceuticals Unipessoal LDA, the largest European pharmaceutical cannabis product manufacturer, is pleased to…

Read more

SOMAÍ Pharmaceuticals has renewed the partnership

July 26, 2023

According to this partnership, Lusófona will develop lab-scale formulations and perform corresponding stability testing. The collaboration…

Read more
SOMAI IG Size 1920 x 950 px 5

SOMAÍ Pharmaceuticals Signs Supply Contract with Cosma Cannabis

June 12, 2023

SOMAÍ Pharmaceuticals has entered into a two-year supply agreement with a well-respected Polish distributor Cosma Cannabis and signed…

Read more
Untitled design 38

SOMAÍ Pharmaceuticals Collaborates with Clever Leaves

May 31, 2023

SOMAÍ Pharmaceuticals has entered into a five-year agreement with Clever Leaves Holdings Inc., a global medicinal cannabis company…

Read more